These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 21788917

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Electrocardiographic changes predict angiographic vasospasm after aneurysmal subarachnoid hemorrhage.
    Ibrahim GM, Macdonald RL.
    Stroke; 2012 Aug; 43(8):2102-7. PubMed ID: 22678087
    [Abstract] [Full Text] [Related]

  • 3. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).
    Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N.
    Acta Neurochir Suppl; 2013 Aug; 115():27-31. PubMed ID: 22890639
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
    Barth M, Capelle HH, Münch E, Thomé C, Fiedler F, Schmiedek P, Vajkoczy P.
    Acta Neurochir (Wien); 2007 Aug; 149(9):911-8; discussion 918. PubMed ID: 17700991
    [Abstract] [Full Text] [Related]

  • 6. Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction.
    Beck J, Raabe A.
    Acta Neurochir Suppl; 2011 Aug; 110(Pt 2):147-50. PubMed ID: 21125461
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage.
    Mayer SA, Aldrich EF, Bruder N, Hmissi A, Macdonald RL, Viarasilpa T, Marr A, Roux S, Higashida RT.
    Stroke; 2019 Oct; 50(10):2738-2744. PubMed ID: 31394993
    [Abstract] [Full Text] [Related]

  • 9. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.
    Fujimura M, Joo JY, Kim JS, Hatta M, Yokoyama Y, Tominaga T.
    Cerebrovasc Dis; 2017 Oct; 44(1-2):59-67. PubMed ID: 28463833
    [Abstract] [Full Text] [Related]

  • 10. Effect of aneurysm treatment modalities on cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
    Suzuki H, Taki W, Prospective Registry of Subarachnoid Aneurysms Treatment (PRESAT) Group.
    Acta Neurochir Suppl; 2013 Oct; 115():99-105. PubMed ID: 22890654
    [Abstract] [Full Text] [Related]

  • 11. Patient phenotypes associated with outcomes after aneurysmal subarachnoid hemorrhage: a principal component analysis.
    Ibrahim GM, Morgan BR, Macdonald RL.
    Stroke; 2014 Mar; 45(3):670-6. PubMed ID: 24425125
    [Abstract] [Full Text] [Related]

  • 12. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.
    Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P.
    J Neurosurg; 2005 Jul; 103(1):9-17. PubMed ID: 16121967
    [Abstract] [Full Text] [Related]

  • 13. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
    Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A, CONSCIOUS-1 Investigators.
    Stroke; 2008 Nov; 39(11):3015-21. PubMed ID: 18688013
    [Abstract] [Full Text] [Related]

  • 14. Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
    Higashida RT, Bruder N, Gupta R, Guzman R, Hmissi A, Marr A, Mayer SA, Roux S, Weidauer S, Aldrich EF.
    World Neurosurg; 2019 Aug; 128():e639-e648. PubMed ID: 31054336
    [Abstract] [Full Text] [Related]

  • 15. Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage.
    Aldrich EF, Higashida R, Hmissi A, Le EJ, Macdonald RL, Marr A, Mayer SA, Roux S, Bruder N.
    J Neurosurg; 2021 May 01; 134(5):1553-1561. PubMed ID: 32442971
    [Abstract] [Full Text] [Related]

  • 16. Patient age and vasospasm after subarachnoid hemorrhage.
    Ryttlefors M, Enblad P, Ronne-Engström E, Persson L, Ilodigwe D, Macdonald RL.
    Neurosurgery; 2010 Oct 01; 67(4):911-7. PubMed ID: 20881555
    [Abstract] [Full Text] [Related]

  • 17. Cerebral vasospasm patterns following aneurysmal subarachnoid hemorrhage: an angiographic study comparing coils with clips.
    Jones J, Sayre J, Chang R, Tian J, Szeder V, Gonzalez N, Jahan R, Vinuela F, Duckwiler G, Tateshima S.
    J Neurointerv Surg; 2015 Nov 01; 7(11):803-7. PubMed ID: 25230840
    [Abstract] [Full Text] [Related]

  • 18. Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.
    Shen J, Pan JW, Fan ZX, Xiong XX, Zhan RY.
    J Neurosurg; 2013 Jul 01; 119(1):180-9. PubMed ID: 23641823
    [Abstract] [Full Text] [Related]

  • 19. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials.
    Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Frey A, Marr A, Roux S, Kassell NF.
    Neurocrit Care; 2010 Dec 01; 13(3):416-24. PubMed ID: 20838933
    [Abstract] [Full Text] [Related]

  • 20. The effects of fluid balance and colloid administration on outcomes in patients with aneurysmal subarachnoid hemorrhage: a propensity score-matched analysis.
    Ibrahim GM, Macdonald RL.
    Neurocrit Care; 2013 Oct 01; 19(2):140-9. PubMed ID: 23715669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.